Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06297941 · ClinicalTrials.gov registry record · Phase 1
Study of REM-422 in Patients With AML or Higher Risk MDS
A Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Remix Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 9
- Study locations
NCT06297941: Recruiting Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Remix Therapeutics.
NCT06297941 is a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes that is actively recruiting participants, run by Remix Therapeutics. The registered enrollment target is 100 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (14% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06297941, a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, is actively recruiting participants, sponsored by Remix Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 9
- Study locations
Study Summary
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML
Primary Outcome
Frequency and severity of Treatment Emergent Adverse Events (TEAEs) will be evaluated according to the NCI-CTCAE version 5.0 and number of participants with Dose Limiting Toxicities will be assessed to determine Safety and Tolerability of REM-422 from the date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 24 months.
Conditions Studied
Interventions
- DRUG REM-422
Study Locations (9)
Other
- Centre Hospitalier Universitaire (CHU) de Bordeaux - Bordeaux
- AP-HP - Hôpital Saint-Louis - Paris
- IUCT-Oncopole - Toulouse
- Institut de Cancerologie Gustave-Roussy - Villejuif
California
- City of Hope - Duarte
Florida
- Moffitt Cancer Center - Tampa
Massachusetts
- Massachusetts General Hospital - Boston
New York
- Memorial Sloan Kettering - New York
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-04-26 |
| Est. Completion | 2027-06-15 |
| Phase | Phase 1 |
What NCT06297941 shows while recruiting
NCT06297941 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (14% lower).
The record links to 4 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which REM-422 is the first listed.
NCT06297941 lists 9 locations in 6 states (Other, California, Florida).
Frequently Asked Questions
What is clinical trial NCT06297941 about?
NCT06297941 is a clinical study titled "Study of REM-422 in Patients With AML or Higher Risk MDS". The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML
What is the current status of trial NCT06297941?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2024-04-26. Estimated completion is 2027-06-15.
What conditions does trial NCT06297941 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Myeloid Leukemia Refractory, Higher-risk Myelodysplastic Syndromes.
What interventions are being tested in trial NCT06297941?
The interventions under investigation include: REM-422 (DRUG).
Who is sponsoring clinical trial NCT06297941?
This trial is sponsored by Remix Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06297941 being conducted?
This trial has 9 study locations across California, Florida, Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06297941's enrollment target sits among peer trials
100 79th of 306 higher than 223 of 306 other Acute Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI